A subscription to JoVE is required to view this content. Sign in or start your free trial.
* These authors contributed equally
This study establishes a set of standard operating procedures (SOPs) for efficiently screening and isolating intestinal bacteria capable of cleaving C-glycosides.
C-glycosides are commonly found in medicinal plants and exhibit extensive structural diversity along with various bioactivities, including antibacterial, anti-inflammatory, antiviral, antioxidant, and antineoplastic activities. In C-glycosides, the anomeric carbon of the sugar moiety is directly connected to an aglycone through carbon-carbon bonding. Compared with O-glycosides, C-glycosides are structurally stable and resistant to acids and enzymes. Consequently, they are typically unbreakable, resulting in poor absorbability and low bioavailability. Interestingly, some intestinal bacteria can cleave C-C glycosidic bonds, providing a specific and environmentally friendly biological approach to degrade C-glycosides. In this study, a set of standard operating procedures (SOPs) was developed for screening intestinal bacteria capable of cleaving C-C glycosidic bonds based on the biotransformation model of natural compounds. The SOPs include the preparation and enrichment of intestinal bacteria, activity-oriented screening, and activity validation in a low-carbon source medium. This methodology provides a foundational reference for researchers aiming to isolate and study these specialized functional bacteria.
C-glycosides are a group of compounds characterized by the direct linkage of glycosyl groups to aglycones through C-C bonds1. In nature, orientin, vitexin, puerarin, and their derivatives are commonly identified as C-glycosides2. These compounds are frequently found in medicinal plants such as Trollius chinensis3 and in animals such as Styela plicata4. Studies have demonstrated that these compounds provide health benefits and exhibit various bioactivities, including antibacterial5,6,
The experiments conducted adhered to local, national, and international biosafety containment regulations appropriate to the specific biosafety hazards associated with each strain. Fecal samples were collected from healthy volunteers who had not taken any drugs for at least one week. Details of the reagents and equipment used are provided in the Table of Materials.
1. Construction of human intestinal bacterial transformation model in vitro
Fecal samples from ten healthy volunteers were screened using transformation experiments, resulting in one sample demonstrating activity in deglycosylating orientin. This finding confirmed the feasibility of screening for active samples. The active sample was isolated using the plate marking method. Based on the morphology and characteristics of the colonies, approximately 18 single bacterial colonies with yellow or white coloration, varied shapes, and uneven edges were selected for further analysis. Among these, only on.......
Standard operating procedure (SOP) for screening human intestinal bacteria capable of cleaving C-glycosides were established. Using these procedures, a pure active strain was successfully obtained, and its deglycosylation property was confirmed through transformation tests. The SOP consists of the preparation and enrichment of intestinal bacteria, activity-oriented screening, and activity validation in a low-carbon source medium.
The most important aspect of the screening process is the u.......
The authors declare no conflicts of interest.
The work was supported by the National Natural Science Foundation of China 82374134.
....Name | Company | Catalog Number | Comments |
Acetonitrile | Thermo Fisher Scientific | F2408R205 | HPLC |
Anaerobic Incubator | Shanghai CIMO Medical Instrument Manufacturing Co., LTD | YQX- II | |
Beef Extract | Beijing Abxing Biotechnology Co., LTD | 01-009 | BR |
Digestive Serum Powder | Beijing Abxing Biotechnology Co., LTD | 01-087 | BR |
Dipotassium Hydrogen Phosphate | Beijing Chemical Works | M26298 | AR |
Disposable Sterile Stool Collection Tube | Lang Fu Co., LTD | 5 mL | |
Distilled Water | Department of Biopharmaceutical, Beijing University of Traditional Chinese Medicine | ||
DMSO | Sigma-Aldrich Corporation | WXBD2861V | AR |
EP Tube | Beijing Biodee Biotechnology Co., LTD | 10 mL/1.5 mL | |
Eppendorf Centrifuge | Eppendorf AG | 5418 | |
Glucose | Beijing Chemical Works | GC205003 | AR |
High Performance Liquid Chromatograph | Shimadzu Corporation | LC-20 | |
High-pressure Steam Sterilizer | Sanyo Denki Shanghai Co., LTD | MLS-3780 | |
Innoval C18 Chromatographic Column | Agela Technologies Co., LTD | 4.6 mm × 250 mm, 5 µm | |
L-cysteine Hydrochloride | Beijing Abxing Biotechnology Co., LTD | BGASY01 | BR |
Liver Extract Powder | Beijing Abxing Biotechnology Co., LTD | 01-085 | BR |
Luteolin | National Institutes for Food and Drug Control | >98% | |
Magnetic Stirrer | Ika Werke Co., LTD | RCT basic | |
Methanol | Thermo Fisher Scientific | 20240901312 | AR |
Millipore Filter Membrane | Sangon Biotech (Shanghai) Co., Ltd. | 0.22 µL × 50 mm | |
Orientin | Yishiming (Beijing) Biotechnology Co., LTD | 19120601 | >98% |
Peptone | Beijing Abxing Biotechnology Co., LTD | 1685787 | BR |
Petri Dish | Beijing Biodee Biotechnology Co., LTD | 150 mm | |
Sodium Chloride | Beijing Abxing Biotechnology Co., LTD | BN20008 | AR |
Sodium Thioglycolate | Shanghai Jianglai Biotechnology Co., LTD | J031S219019 | AR |
Soluble Starch | Beijing Abxing Biotechnology Co., LTD | S9765 | BR |
Soya Peptone | Beijing Abxing Biotechnology Co., LTD | 2147955 | BR |
Tryptone | Agela Technologies Co., LTD | 1685787 | BR |
Ultrasonic Cleaner | Kun Shan Ultrasonic Instruments Co., LTD | KQ-500DE | |
Yeast Extract | Beijing Abxing Biotechnology Co., LTD | 01-014 | BR |
Request permission to reuse the text or figures of this JoVE article
Request PermissionExplore More Articles
This article has been published
Video Coming Soon
Copyright © 2025 MyJoVE Corporation. All rights reserved